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Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect
the heart from the detrimental effects of acute ischaemia–reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard,
although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting,
only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure
to thoroughly assess the cardioprotective efficacyof these novel therapies in suitably designedpreclinical experimental animal models. Therefore,
the aim of this Position Paper by the European Societyof Cardiology Working Group Cellular Biologyof the Heart is toprovide recommendations
for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the
likelihood of success in translating these new treatments into improved clinical outcomes.
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1. Introduction
Ischaemic heart disease (IHD) is the leading cause of death and disability
worldwide. Therefore, novel therapies are required to protect the myo-
cardium against the detrimental effects of acute ischaemia–reperfusion
injury (I/R injury) in patients with IHD, so as to reduce lethal cardiac
arrhythmias and cardiomyocyte death, preserve cardiac function and
prevent the onset of heart failure, and improve patient survival.1
Despite a large number of novel cardioprotective strategies (both
pharmacological and non-pharmacological) being discovered in the
research laboratory, their translation into the clinical setting to
improve patient outcomes has been largely disappointing. The reasons
for this failure are multiple and can be divided into two main categories:
(i) the failure to rigorously test the novel cardioprotective therapy in the
preclinical setting before embarking into the clinical arena.2,3 This is the
topic of the current European Society of Cardiology (ESC) Working
Group (WG) Cellular Biology of the Heart Position Paper; and (ii) inad-
equate design of the clinical studies for testing the novel therapy. This
subject has been extensively reviewed in our recently published ESC
WG Cellular Biology of the Heart Position Papers4,5 and elsewhere.2,6
In brief, the major issues with the study design of previous clinical cardi-
oprotection studies relate to following areas: the selection of the patient
population; taking into account knownconfounders of cardioprotection
(such as age, diabetes, and hypertension); the timing of the administra-
tion of the cardioprotective therapy; and choosing the relevant end-
points for assessing the efficacy of the cardioprotective therapy.
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The National Heart and Lung Institute (NHLI) have convened a WG,7
to discuss the reasons for the failure to translate potential cardioprotec-
tive therapies into the clinic, and they made several recommendations,
including the formation of an US network of research laboratories
with expertise in small (mice, rat, and rabbit) and large (pig) acute I/R
injury models. The remit of the NIH (National Institute of Health)
CAESAR (Consortium for preclinicAl assESsment of cARdioprotective
therapies) Cardioprotection Consortium (http://www.nihcaesar.org) is
to systematically test a particular novel cardioprotective therapy using a
multicentre randomized controlled study approach before venturing
into the clinical setting. Interestingly, of the agents tested so far by the
CAESAR Cardioprotection Consortium, sodium nitrite and sildenafil
citrate have both failed to limit myocardial infarction (MI) size, despite
prior studies reporting beneficial effects with these therapies.8,9
In the present ESC WG Cellular Biology of the Heart Position Paper,
we review the current approaches used for determining which novel
cardioprotective therapies discovered in the research laboratory are
investigated in the clinical setting. We recommend new strategies for
optimizing this process, in order to limit the novel cardioprotective ther-
apies selected for testing in the clinical setting to those most likely to
succeed in improving patient outcomes.
2. Why has the translation of novel
cardioprotective therapies into
improved clinical outcomes been so
difficult?
It takes a triad of: (i) creative and innovative basic scientists who generate
a novel mechanistic insight into the signal transduction of cardioprotec-
tive strategies, and identify novel signalling molecules, which may even-
tually be suited for drug development; (ii) enthusiastic physician
scientists with a personal background in basic science and thorough clin-
ical experience in the care of patients subjected to acute I/R injury, who
can eventually perform proof-of-concept trials; and finally (iii) a dedi-
cated pharmaceutical company with sufficient financial and logistic cap-
abilities to develop a molecule of interest into a drug for the market.
With respect to the largely disappointing translationof cardioprotection
into clinical practice over the last decades, we have seen failures at every
single level of the above triad and even more so in their interaction.
The basic science in the field of cardioprotection is increasingly being
performed by non-physicians, oriented towards molecular and (sub-)
cellular approaches and using largely reductionist in vitro cell models
or at best rodent preparations: the strength of this development is the
generation of truly novel mechanistic insights on a basic level of molecu-
lar and cellular biology, and the disadvantage is its ever increasing
distance from clinical reality. Of note, the use of less reductionist and
a more integrative large mammal model of regional myocardial I/R
which are much closer to clinical reality is increasingly rare, in part sec-
ondary to animal welfare restrictions, but also secondary to expenses.
Even when large mammal models are used, they most often do not
take into consideration age, co-morbidities, and co-medications which
a patient with an acute coronary syndrome would most likely have.
The species of physician scientists who have both a personal background
inbasic scienceexperimentationandclinical experience in the treatment
of patients with acute I/R injury is increasingly rare and almost extinct.
These are the people who would be enthusiastic about a novel basic
mechanism and/or molecule and would potentially undertake a
proof-of-concept small clinical trial to see whether or not this mechan-
ism and/or molecule might also work in patients. And finally, a pharma-
ceutical company would need to have interest in a potential drug that
might not translate into a blockbuster for daily intake over a long
period of time but possibly just for one single treatment just before or
at reperfusion of an acute MI (AMI). The interaction between the
three potential partners has also been problematic in the past. Basic
scientists have been overlyoptimistic and advocated the newly identified
molecules for treating patients before even testing the translation to
more integrative large mammal models of regional myocardial ischae-
mia/reperfusion. Also, pharmaceutical companies have prematurely
embarked on novel signalling molecules for drug development, only to
later find out that the experimental data were not so solid and non-
controversial as initially assumed. An extremely important step in the
translation of cardioprotection is the conduct of small proof-of-concept
clinical trials. Such trials have more recently established proof-of-
concept forprotection bypostconditioning and remote preconditioning
in elective and emergency I/R settings;10 –14 of note, this success was
related to mechanical strategies or to established, no longer patent-
protected drugs where there was no involvement of pharmaceutical
industry.
3. Statistical considerations
in research
A recurring observation in research is that the promise of impressive and
significant results in preclinical studies tends to gradually evaporate
during subsequent clinical trials. This frustrating phenomenon is hardly
restricted to studies of cardioprotection. Indeed, a widely discussed
publication of statistical simulations arrived at the disturbing conclusion
that most current published research findings are, in fact, false.15 This is
notdue to fraudbut is theexpectedoutcomewhenmany investigators in
a large scientific field conduct numerous small studies, with a bias
towards the publication of positive results and the presence of other
biases such as flexibility in experimental design.15 While some of these
problems can be difficult to overcome,15 a number of specific recom-
mendations can be given for preclinical animal studies that should be
completed before progressing to clinical trials.
First, of course, it is essential to adhere to the usual expectations of a
well-designed experiment, including the use of contemporaneous con-
trols, correct vehicle controls, and appropriate use of ANOVA for stat-
istical analysis of multiple groups. It is important to be aware that while
the arbitrarily chosen P-value of 0.05 is indicative of significance, it does
not necessarily imply that reproducibility will occur at least 95% of the
time.16
Wherever possible, the statistical power of an experiment should be
calculated a priori, from previously existing data, and the required
number of animals per group calculated before embarking on experi-
ments. Not only are underpowered experiments less likely to detect sig-
nificant effects, when they do, they are less likely to represent a true
effect that will be reproducible. Despite the drive to reduce animal
numbers for ethical reasons, it must be recognized that insufficiently
powered experiments are themselves, wasteful, misleading, and hence
unethical. The Animal Research: Reporting In Vivo Experiments
(ARRIVE) guidelines17 specify the importance of calculating sample
size and power, but such calculations assume an accurate measurement
of the expected size of effects. A recent damning indictment of studies in
the neuroscience field demonstrates that many studies are severely
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underpowered.18 It cannot be assumed that studies in the cardioprotec-
tion field would fare much better.
Other important recommendations are that exclusion criteria be
defined in advance, rigorously adhered to, and reported in publications.
The animals and treatments should be randomized, with the researcher
blinded as to whether an individual animal is receiving vehicle or drug.
The analysis should also be performed blinded to the treatment
group. Any conflicts of interest must be reported.
Finally, it is the responsibilityof the researcher to ensure that results as
reported are unbiased and as accurate a representation of data as
possible. Recent events in cardiovascular research have highlighted
the importance of vigilance in this regard.
Of note, a useful ‘checklist’ of six points for evaluating published pre-
clinical research includes: blinding of experiments, repetition of experi-
ments, selection of results presented, presence of positive and negative
controls, validation of reagents such as antibodies, and the use of appro-
priate statistical tests19 (Table 1). Previous studies have shown that when
such guidelines are not adhered to, the odds of obtaining significant
effects in animal studies can be approximately three-fold higher.20 It
has been proposed that animal trials should be pre-registered, similar
to clinical trials.15 While this approach is currently rare in basic
science, possibilities do exist (e.g. The Open Science Framework21),
and their expanded use might help to reduce a positive publication bias.
One effective means of avoiding many of the above pitfalls is to ensure
experiments are replicated by several independent groups. In fact, such a
multicentre design was first used in the cardioprotection field in 2000, in
order to examine the efficacy of an adenosine A1 receptor agonist in
limiting infarct size in rabbits when administered at reperfusion. The
results of this rigorous trial were negative.22 However, the disappoint-
ment of negative results must be weighed against the benefit of being
abletorefocuseffortsondrugs,whicharemore likely tobeclinically trans-
latable.3 Subsequently, a workshop held in June 2003 by the NHLI recom-
mended that an independent organization for the preclinical assessment
of cardioprotective therapies be established. This has now been realized
in a publically accessible infrastructure called CAESAR. The remit of this
consortium is to test promising therapies in three species (in vivo acute
I/R injury rodent, rabbit, and porcine models) across three centres.23
A logical approach would be to develop an equivalent European facility
for preclinical testing of cardioprotective therapies.
4. Improving the experimental
models of acute I/R injury
Once acardioprotective therapy hasbeen proved to be safe andefficient
in preclinical animal studies, it is estimated that only 20% of these are
translated into the clinical setting for patient benefit.24 The translation
from bench to bedside would certainly be improved if preclinical
studies were more appropriately designed.24 A non-adapted experi-
mental protocol, an inadequate choice of the animal model, the exclu-
sion of confounding factors will all contribute to limiting the chance of
a successful translation to humans.
4.1 Selecting the appropriate experimental
model of acute I/R injury
When designing the experimental study for testing the novel cardiopro-
tective therapy, careful selection of the appropriate in vitro (‘within
glass’), ex vivo (‘outside of living’), or in vivo (‘within the living’) model of
acute I/R injury is required.
4.1.1 Cell models of simulated acute I/R injury
The use of cell models of simulated acute I/R injury can allow one to over-
come the ethical problemsand costs (fromtime and resources)of experi-
menting on animals. They can be tightly controlled, can usually be
undertaken quicker than ex vivo and in vivo experiments models of acute
I/R injury, and can assess the direct effect of the novel cardioprotective
therapy on the cardiomyocyte itself. However, they do not accurately re-
present the organism as a whole, and do not include the complex interac-
tions of different cell types and/or effector systems.
The primary cell of the heart, which is damaged by acute I/R injury, is
the cardiomyocyte. The primary adult cardiomyocyte is the most closely
related to the adult heart in terms of characteristics and is most often
harvested from mice, rats, or rabbits, but can also be obtained from
guinea pig, dog, pig, and human. A number of different cells have been
used in place of adult primary cardiomyocytes in experimental models
of acute I/R injury, including HL-1 cells (derived from murine atrial myo-
blasts),25 H9C2 cells (a rat cardiomyoblast cell line),26 C2C12 cells (a
murine myoblast cell line),27 (embryonic) stem cell-derived cardiomyo-
cytes,28 and neonatal cardiomyocytes.29 Although these cells may
possess some of the key features of adult cardiomyocytes such as an
organized internal structure, cell–cell contacts, high oxygen consump-
tion, and spontaneous beating, several key differences such as the
ability to proliferate and signal transduction pathways might affect
their use as surrogates for primary adult cardiomyocytes. Adult progeni-
torcell-derived cardiomyocytes are electrophysiologically more mature
cardiomyocytes than those derived from young (foetal) progenitor
cells,30 indicating that several stages of maturation exist in cardiomyo-
cytes, and this could potentially affect the response to cardioprotection.
The simulated acute I/R injury model itself can vary, with the use of a
variety of different insults to simulate acute I/R injury including metabolic
inhibition (using cyanide),31 hypoxic pelleting of cells (using surface
mineral oil),32,33 and oxidative stress (using hydrogen peroxide).34
However, these experimental models are unable to recapitulate the
complex conditions of acute I/R injury.
For a cell model of simulated acute I/R injury, we recommend that
primary adult cardiomyocytes should be used with ischaemia simulated
by incubating the cells in ischaemic buffer (de-oxygenated and substrate-
free) in an air-tight hypoxic chamber. Reperfusion can then be simulated
by replacing the ischaemic buffer with normal oxygenated buffer and
removing the cells from the hypoxic chamber. The simulated ischaemic
and reperfusion times should be characterized for the cell type with the
overall aim to induce 50% of cardiomyocyte death.
4.1.2 Ex vivo models of acute myocardial I/R injury
Ex vivo models of myocardial acute I/R injury using the isolated perfused
heart are often used to assess the cardioprotective efficacy of a novel
Table 1 Six points ‘checklist’ for evaluating published
preclinical research studies19
1. Were the experiments performed blinded? 3
2. Were basic experiments repeated? 3
3. Were all the results presented? 3
4. Were there positive and negative controls? 3
5. Were reagents validated? 3
6. Were statistical analysis tests appropriate? 3
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therapy, as they can be carried out relatively rapidly, and they often
produce reproducible results in the absence of systematic factors in
the blood. The Langendorff-perfused heart was first used at the end of
the 19th century, and comprises mounting the isolated heart on the
aortic cannula of a Langendorff perfusion apparatus and retrogradely
perfusing the heart at a constant flow or constant pressure, using
blood or oxygenated buffer (typically Krebs–Henseleit solution).35,36
This model is most often used for perfusing hearts from small animals
such as mice, rats, rabbits, and guinea pigs, but it can also be used for
larger animal hearts from pig and even human hearts.37,38 The ischaemic
insult is induced regionally by coronary ligation (thereby mimicking
a clinical AMI) or globally via partial or complete reduction of the flow
(thereby mimicking the ischaemic conditions of cardiac bypass surgery).
The isolated working heart model of acute I/R injury allows one to
perfuse the heart in the anterograde manner via the left atrium, filling
the left ventricle and ejected via the aorta against a variable afterload.
The advantages of this model over Langendorff perfusion include the
ability to modulate both preload and afterload on the heart, and this
model allows low-flow ischaemia.39
Although the ex vivo Langendorff and isolated working heart models
are useful for assessing the cardioprotective efficacy of novel therapies,
the complexity of the in vivo setting is not recapitulated by these models
and, for this reason, they should only be used as an initial step in the pre-
clinical assessment of novel cardioprotective therapies.40
4.1.3 In vivo heart models of acute I/R injury
In the majority of preclinical in vivo animal models of acute I/R injury, the
main left coronary is occluded to induce complete regional ischaemia for
30–90 min depending on the animal species, followed by coronary
reflow to induce myocardial reperfusion. The duration of reperfusion
can vary depending on the particular animal model of acute I/R injury
(see later). This experimental model of acute I/R injury best represents
the clinical setting of a patient presenting with an acute ST-elevation
myocardial infarction (STEMI), who is reperfused by primary percutan-
eous coronary intervention (PPCI).
A variety of methods have been employed to induce AMI. Left
anterior descending coronary artery ligation following left thoracotomy
is by far the most commonly used technique, although the model can be
time-consuming and the recovery model is associated with a high mor-
tality rate, varying from 20 to 50% according to the species.41
Closed-chest models of AMI, in which occlusion is performed by
intracoronary devices (most frequently by catheterization and inflation
of an angioplasty balloon), can be performed in rodents and large
animals.42,43 These models have the advantage of not being associated
with the surgical trauma and inflammation associated with the open-
chest approach.
Experimental coronary microembolization using intracoronary infu-
sion of microparticles can serve as a model of an acute coronary syn-
drome simulating the microvascular obstruction and dysfunction,
which occurs in these patients.44 Repetitive intracoronary infusion of
microparticles induces severe myocardial dysfunction and has been
used as an experimental model of ischaemic heart failure.45 Intracoron-
ary infusion of inert microspheres induces embolization of the coronary
microcirculation, where the level of vascular obstruction depends on
microsphere diameter. The initial response to coronary microemboliza-
tion is an immediate decrease in coronary blood flow, which is followed
bya reactive hyperaemia response.46 Since coronary microembolization
induces permanent coronary microvascular obstruction, patchy MI with
a subsequent inflammatory reaction ensues.47 Infiltration of leucocytes
goes along with increased expression of tumour necrosis factor alpha
(TNFa),48 and a signal transduction of nitric oxide, sphingosine, and re-
active oxygen species formation with subsequent oxidativemodification
of the contractilemachinery induces contractile dysfunction.49,50 On the
other hand, the enhanced expression of TNFa following coronary
microembolization can protect from subsequent MI,51 and this may par-
tially explain the protection observed clinically with pre-infarction
angina.52,53
In summary, if using a cell-based model of simulated acute I/R injury to
assess the novel cardioprotective therapy, primary adult cardiomyocytes
should be used where possible. Ex vivo isolated perfused heart models of
acute I/R injury may be used to ‘screen’ the novel therapy where applicable,
but it is essential to demonstrate cardioprotective efficacy in small and large
in vivo animal models of acute I/R injury.
4.1.4 Specialist models of acute myocardial I/R injury
There are other clinical settings in which the heart is subjected to acute I/
R injury such as cardiac bypass surgery, cardiac arrest (CA), and cardiac
transplantation, which arenot represented in the preclinical settingusing
the above acute I/R injury models. In this case, more specialized preclin-
ical animal I/R injury models are required, which better reflect these clin-
ical settings.
4.1.4.1 Cardiopulmonary bypass surgery model
The clinical setting of cardiopulmonary bypass (CPB) surgery provides a
controlled setting for investigating the efficacy of novel cardioprotective
strategies against perioperative myocardial injury, the extent of which
can be measured using serum cardiac enzymes. However, this model
of acute I/R injury is complicated by several factors: (i) the presence of
other cardioprotective strategies such as cardioplegia and hypothermia;
(ii) the presence of concomitant medication which may potentially be
cardioprotective such as inhaled anaesthetics, nitrates, and opioids;
and (iii) the heart is subjected to a variety of different forms of injury
including global I/R injury, direct injury from handling of the heart, coron-
ary microembolization, and inflammatory injury from the CPB circuit.
Therefore, in order to simulate the clinical setting of cardiac bypass
surgery, a specific I/R injury model of CPB may be better suited to test
novel cardioprotective therapies.54 In this regard, there are rat models
of CPB which are well-established and have the following advantages
when compared with larger animal models: rats are relatively cheap,
easy to survive, and do not require intensive care units (ICUs) after
surgery. More realistic CPB models of global myocardial I/R injury can
be achieved in large animals (such as dogs or pigs) with median sternot-
omy, aortic cross-clamping, and direct perfusion with cardioplegic solu-
tion leading to CA.55 However, such animal models are expensive and
require the presence of ICU for recovery studies, and the evaluation
of organ damage is difficult to standardize.
4.1.4.2 Cardiac arrest models
Although timely cardiopulmonary resuscitation (CPR) can result in
25–50% of patients achieving restoration of spontaneous circulation
(ROSC), only 2–10% of patients survive without any neurological
deficit. Given the poor outcome in this patient group, novel cardiopro-
tective therapies are required to protect the heart against acute I/R
injury, reduce arrhythmias and cardiomyocyte death, and preserve left
ventricular (LV) systolic function. Apart from brain injury, one major
reason for this poor outcome post-CPR is due to the post-CA
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syndrome, which comprises in part systemic I/R injury and post-CPR
myocardial dysfunction which can be present in 50% of successfully
resuscitated patients. In patients presenting with a CA, the heart is sub-
jected to global ischaemic injury and following timely CPR, and if restor-
ation of ROSC is successful, the heart is subjected to global reperfusion
injury, the effects of which are cardiomyocyte death, and post-CPR myo-
cardial dysfunction.
There are both small (murine and rat) and large animal (rabbit and pig)
modelsof acute I/R injury,which are able to simulateCA, successfulCPR,
and ROSC. In these models, CA is induced using either an electrode to
cause ventricular fibrillation or anoxia (stopping ventilation) and is left
untreated for several minutes, then CPR is started (ventilations and
external cardiac compressions) for a period of time, followed by defib-
rillation to achieve ROSC. In these models, the most common endpoints
of cardioprotection include death, cerebral function, myocardial injury,
and LV systolic function. These animal CA models have been used to in-
vestigate a number of cardioprotective therapies, including inhaled
anaesthetics56– 58 and cyclosporine A.59,60
4.1.4.3 Cardiac transplantation models
When the heart is removed from the donor patient, it is subjected to
acute global ischaemic injury, although this is prevented by cardioplegic
solution and hypothermia. The heart remains ischaemic until it is
implanted into the recipient heart where it is subjected to acute global
reperfusion injury. Acute myocardial I/R injury sustained during
cardiac transplantation can contribute to graft vasculopathy and
failure.61 Therefore, novel cardioprotective strategies are required to
protect the transplanted heart from the detrimental effects of acute
I/R injury in order to preserve graft function. In this regard, a number
of preclinical studies have investigated a variety of cardioprotective
interventions applied to the donor heart including pharmacological
agents (i.e. sodium–hydrogen exchange inhibitors) and mechanical
interventions (conditioning) [reviewed in ref. (61–63)].
4.1.4.4 Computational models
In silico (‘in silicon’) systems, in which mathematical models of a physio-
logical or pharmacological system are developed and tested on a com-
puter, are a hybrid of in vivo/ex vivo and in vitro techniques.64 Like in vivo
techniques, in silico experiments are designed to mimic the behaviour
of organisms in their entirety.65 However, like in vitro experiments,
they do not require actual experimentation on animal subjects, and con-
ditions can be better controlled.65 To date, several studies have
reported a number of analyses and protocols in relation to myocardial
ischaemia and reperfusion (reviewed in Ferrero et al.66). Future work
should focus on broadening the applicability of these modelling techni-
ques outside of the realm of pharmacology, and towards novel cardio-
protective strategies.
In summary, there exist small and large animal models of CPB, CA, and
cardiac transplantation for investigating novel cardioprotective therapies,
which better represent the patient subjected to acute I/R injury in these clinical
settings.
4.2 Selecting the appropriate experimental
protocol
After selecting the appropriate model of ischaemia and reperfusion,
careful consideration needs to be taken in the design of the experimental
protocol.
4.2.1 Choice of anaesthetic
Although volatile anaesthetics arecurrently the preferreddrug of choice
to anaesthetize animals in preclinical experiments, their use in cardio-
protective studies has been limited, due to their inherent cardioprotec-
tive properties.19,67,68 Ex vivo, the use of sodium pentobarbitone remains
the anaesthetic of choice for isolated heart studies as isoflurane and
sevoflurane reduce MI size and improve functional parameters, when
administered prior to ischaemia.69 When conducting in vivo experi-
ments, the choice of the anaesthetic agent is critical as it may directly
affect the measurement of different endpoints. As an example, the use
of some anaesthetics may modify the heart rate in such a way that it
may compromise the capture of data by echocardiography.70,71
4.2.2 Duration of ischaemia
Inmostexperimental models of AMI, the duration of the index ischaemic
episode is selected so as to generate 50% cell death or an MI size of 50%
of the area-at-risk (AAR). This allows the experimental acute I/R injury
model to determine whether the novel cardioprotective therapy is
beneficial or detrimental. However, the response of the heart to I/R
injury varies depending on the animal model used. In rodent models of
AMI, 30–40 min of either regional or global myocardial ischaemia is
sufficient to induce an MI size of 50% of the AAR, whereas in porcine
and primate MI models, which are more representative of the human
physiology in terms of ischaemic time, 50–90 min of myocardial ischae-
mia is required to achieve equivalent levels of infarction.72 –74 Crucially,
in patients presenting with an AMI who are treated by reperfusion
therapy, the time from onset of symptoms to reperfusion can vary
from 30 min to 12 h, with evidence of MI (troponin release) developing
after 30 min.40,75 Even then, the MI size in patients is highly variable and in
theory, it can range between 5 and 40% of the LV volume depending on
the site of the acute coronary occlusion. However, in clinical cardiopro-
tection studies in which both MI size and the AAR have been measured
using cardiac MRI, mean MI size as a % LV volume has been reported as
15–25%, and the mean infarct size as a % of the AAR has been found to
be 39–70%.10,74,76
4.2.3 Duration and mode of reperfusion
Because this review focuses on novel cardioprotective therapies for pre-
venting acute I/R injury, we do not review experimental models of
permanent coronary artery ligation, which are most often used to inves-
tigate post-MI heart failure. The reperfusion time used in experimental
models of acute I/R injury varies with the model. In some cases, short
periods of reperfusion lasting only 2–3 h are used at the end of which
the experiment is terminated and MI size determined. Although this par-
ticular model allows rapid assessment of the cardioprotective efficacy of
the novel therapy, it does not adequately represent the clinical setting in
which MI assessment may occur several days after reperfusion. There-
fore, in order to accurately assess the cardioprotective efficacy of the
novel therapy, extended periods of reperfusion should be used where
possible, although for these prolonged periods of reperfusion, the
animal has to be recovered from anaesthesia, making this approach tech-
nically more demanding. Long-term cardioprotective efficacy is often
assessed at 2–4 weeks post-MI, an experimental approach that allows
one to also determine the effect of the novel cardioprotective therapy
on post-MI LV remodelling.1 The availability of echocardiography and
small and large animal cardiac MRI (MRI) allow one to serially assess
the cardioprotective efficacy of the novel therapy on MI size, cardiac
function, and post-MI remodelling over time.40
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4.2.4 Drug administration
An important aspect to consider when testing the efficacy of a novel
cardioprotective therapy is to ensure that the timing of the drug admin-
istration takes into account the clinical setting of the acute I/R injury.
If myocardial reperfusion injury in PPCI-treated STEMI patients is
the intended clinical target, then it would be essential to demonstrate
that the novel cardioprotective therapy can limit MI size when admi-
nistered just prior or at the onset of reperfusion. Conversely, if the
therapy is intended for use in clinical settings in which the onset of
acute I/R injury can be reliably anticipated such as in elective PPCI or
coronary artery bypass graft surgery, then it would be essential to
show that the novel cardioprotective therapy is effective when adminis-
tered prior to the index ischaemic event. Most importantly, the use of
appropriate vehicle/sham control groups needs to be included in the
study, especially when invasive mechanical therapeutic interventions
are being considered.
4.2.5 Endpoints for assessing cardioprotection
A number of different endpoints have been measured to assess the car-
dioprotective efficacy of a novel therapy. The most robust and critical
endpoint is to demonstrate a reduction in cardiomyocyte death,
which can be easily measured by cell viability (in cell models of simulated
acute I/R insult) or myocardial infarct size (in ex vivo and in vivo models of
acute I/R insult). Other endpoints which are often used include arrhyth-
mias, LV geometry and function, and so forth, all of which are surrogate
endpoints that can be used to confirm cardioprotection.
4.2.5.1 Myocardial infarct size
It is essential to demonstrate that a novel cardioprotective therapy can
reduce cardiomyocyte death inducedbyacute I/R injury. Following a sus-
tained episode of lethal I/R, the major determinants of MI size are the
AAR of infarction, the duration of ischaemia, and the presence of collat-
erals.62 Therefore, providing the index ischaemic time is fixed, significant
collateralization has been excluded or accounted for, and MI size should
be expressed as the percentage of the AAR. In most animal I/R injury
studies, MI size and the AAR are delineated using dual staining with
triphenyltetrazolium chloride (TTC) and Evan’s Blue [for more details
onMI sizemeasurement techniques, see review in ref. (35,77)]. Although
this technique is well established and widely used, it is important to keep
in mind that it has some limitations as it relies on the wash-out of dehy-
drogenases, and therefore the histological determination of MI size may
be a more reliable and robust technique. A complimentary approach to
measuring MI size by either TTC or histology is to assess MI size using
cardiac enzymes.
4.2.5.2 Cardiac enzyme release
The measurement of cardiac enzyme release either in the serum (in vivo
studies) or perfusate (isolated heart studies) allows a dynamic assess-
ment of cardiomyocyte death as reperfusion progresses, providing an
insight into the potential mechanisms underlying I/R injury. It also pro-
vides an alternative assessment of cardioprotective efficacy for a novel
therapy, which compliments MI size measured by TTC or histology.
In the past, creatine kinase and lactate dehydrogenase (LDH) have
been used, but more recently troponins T and I have been used to
measure myocardial necrosis in experimental I/R injury models.78,79 In
the post-ischaemic reperfused isolated rat heart, there appear to be
two distinct peaks of LDH release, one occurring in the first few
minutes of reperfusion, and the second taking place later between
30 and 120 min reperfusion, potentially reflecting different phases of
reperfusion injury—of note, these peaks were differentially attenuated
by the cardioprotective therapy.79 The potential existence of this phe-
nomenon in vivo and the mechanism underlying the two different
peaks of reperfusion injury need to be investigated as the kinetic of
cardiac enzyme release may differ between in vitro and in vivo conditions.
4.2.5.3 Functional endpoints
Functional endpoints such as LV development pressure and LV ejection
fraction are sometimes used to assess the cardioprotective efficacy of
novel therapies. However, reduced contractile function in the setting
of myocardial I/R is difficult to interpret, as it may reflect adaptation to
ischaemia as in hibernating myocardium,80,81 reversible injury as in stun-
ning,63 irreversible injury from infarction, or remodelling post-MI.1
Therefore, functional data should not be considered in isolation and
should be used to compliment measured MI size. In the isolated heart,
the use of an intraventricular balloon connected to a transducer/chart
recorder will give useful functional parameters including heart rate
and LV developed pressure.35 Insertion of a catheter can capture real-
time right or LV pressure–volume loops, and these can be used in vitro
or in vivo to measure the beat-to-beat variations in cardiac systolic and
diastolic function. An ECG can assess arrhythmias and echocardiog-
raphy can monitor cardiac dimensions and contractile function.
4.2.5.4 Long-term cardioprotection
The long-term cardioprotective effects of novel therapies can be inves-
tigated in terms of final MI size and post-MI LV remodelling as measured
by LV dimensions and function using either cardiac echocardiography or
MRI. There is also an opportunity to assess the effects of a novel cardi-
oprotective therapy on post-MI survival.
In summary, MI size is the most reliable and robust endpoint for assessing
the cardioprotective efficacy of novel therapies. The duration of the index
ischaemia used should be sufficient to cause 50% cardiomyocyte death or
an MI size of 50% of the AAR. Extended periods of reperfusion (24–72 h)
are preferred as these allow one to evaluate the long-term cardioprotective
efficacy of the novel therapy. Careful consideration of the intended clinical
application of the new treatment should be given when timing the administra-
tion of the novel cardioprotective therapy in the preclinical setting.
4.3 Selecting the appropriate animal model
Preclinical animal AMI models are not always predictive, and in some
cases they poorly represent the clinical setting.2 Inadequate selection
of the animal species could importantly contribute to spurious or incon-
sistent results, as well as unnecessary animal use. The lack of prediction
and conflicting findings are related, in some instances, to species-
dependent sensitivity to myocardial I/R injury—that does not necessar-
ily reflect disease in humans—which in turn, is modulated by anatomical
factors, metabolism, idiosyncratic toxicity reactions, immunological
responses, as well as co-morbidities and their routine medications.
4.3.1 Species, strain, and genetically modified animals
The common use of rat and murine AMI models in the research field of
cardioprotection is driven more by practicality and cost, rather than
by relevance to the clinical setting. However, some cardioprotective
strategies that have proved to protect in experimental conditions
using initially a rat/mouse model have been translated to humans
in small proof-of-concept clinical studies, making the use of these
models relevant to delineate concepts and cellular signalling events. It
is important to keep in mind that reproducibility of cardioprotective
strategies may also differ between strains in the same species. Genetic
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divergence between different inbred mouse strains leads to variations in
ex vivo and in vivo cardiac function82 and also infarct size.34 These physio-
logical differences, and also different responses to the environment and
stress from one strain of mice to another strain of mice, may explain var-
iations in MI sizes when mice are subjected to the exactly same protocol
of I/R.34,83
The use of mice is the preferred animal model for genetic manipula-
tion. However, many knockout animals have not been fully character-
ized, and the manipulation of one gene may lead to multiple
pathophysiological adaptations which are not controlled by the
researchers.Therefore, the conclusions of these studies should be inter-
preted with caution.24 When studying novel cardioprotective therapies
in genetically modified animals, the choice of the littermate wild-type
control over the original strain mouse is also critical as a small genetic
variation often incorrectly considered as irrelevant by the researchers,
may affect the outcome of the study. Hence, six cycles of ischaemia
and reperfusion as an ischaemic postconditioning cardioprotective
strategy in the isolated mouse heart model subjected to ischaemia–
reperfusion reduced the infarct size in C57BL/6 pure mice, but failed
to protect in C57BL/6 floxed signal transducer and activator of tran-
scription (STAT-3) mice commonly used as littermate controls in
studies with STAT-3 knockout mice.83
4.3.2 Small-to-large animals
Animal size is a critical determinant of the experimental strategy and may
be a limiting factor in itself for certain procedures (i.e. technical challenge
for the instrumentation of coronary vessels in small animals, unafford-
able costs derived from the wider biodistribution of some engineered
compounds in large animals). Small-sized animals, typically mice and
rats, and to a lesser extent guinea pigs and rabbits, are extensively
used in cardioprotection studies, mainly due to their lower cost,
shorter gestation time, easier handling, and well-characterized native
or manipulated genetic profile.84 This practice is facilitated by the avail-
ability of novel technological tools that allow the use of rodents for in vivo
cardiac echocardiography and MRI.85 In contrast, the use of large animals
(primarily pigs and dogs, and more exceptionally sheep and non-human
primates) is limited by their high cost, difficult maintenance, requirement
of skilled personnel, and increased individual and social ethical concerns.
As a general rule, there is an inverse relationship between body weight
and heart rate across animal species due to size-dependent differences
in a metabolic demand.86,87 Consequently, oxygen consumption and
cardiac contractile activity are higher in small animals, resulting in
increased free radical production, reduced contraction-relaxation
times, and differences in calcium handling and myofilament protein iso-
forms.87,88 In rodents, sarco/endoplasmic reticulum calcium ATPase
(SERCA) is responsible for the sequestration of 92% of cytosolic
calcium and only the remaining 8% is extruded by the sarcolemmal
sodium/calcium exchange (NCX),88 whereas in humans SERCA and
NCX account for 76 and 24% of calcium normalization, respectively.89
These differences may be particularly relevant when testing pharmaco-
logical cardioprotective strategies during the first minutes of reperfu-
sion, in which cell death develops mainly as a consequence of
cytosolic calcium overload and rapid sarcoplasmic reticulum-driven
calcium oscillations.90 However, large body size does not warrant ana-
tomical resemblance with the human cardiovascular system. The
extent of collateralization and atherosclerotic resistance/blood lipid
profile confer non-comparable native cardioprotection after an ischae-
mic insult. A well-developed coronary collateral circulation is present in
dogs and cats (and guinea pigs), whereas it is negligible in pigs and
primates (and rodents).91 Similarly, most dog strains are relatively resist-
ant to develop atherosclerotic disease.84 Although selective breeding
for production purposes have distanced adult swine heart/body
weight relationship from that present in humans, pigs are considered
the better suited animals for cardioprotection studies,92 because they
share with humans similar coronary circulation anatomy and aortic hist-
ology, as well as vulnerability to develop spontaneous or diet-induced
vulnerable atherosclerotic plaques.93 Also, and unlike other animals,
pigs may develop coronary restenosis after gradual occlusion.94 Pri-
mates are notoriously resistant to MI and develop only 17% infarct
size of the AAR after 90 min coronary occlusion.95 Finally, it is important
to take into account that some of the most powerful cardioprotective
strategies like pre- and postconditioning have been proved to be more
dependent on age, co-morbidities, and drugs than on animal size.96,97
4.3.3 Gender and age
Most of the experimental studies confirm the clinical observations that
female hearts have an increased resistance to I/R injury compared with
male hearts [for review, see ref. (96,98–100)]. Cardioprotective strat-
egies such as ischaemic pre- and postconditioning also appear tobe influ-
enced by the gender of the animal, and menopause may affect resistance
towards I/R injury during aging in females.98 Similarly, while pre- and
postconditioning attenuate I/R injury in young animal hearts, most
studies suggest a loss of protection in aged hearts [for review, see ref.
(97,101,102)].
4.3.4 Co-morbidities
Hyperlipidaemia was the first cardiovascular risk factor or co-morbidity
to be associated with the loss of cardioprotection by preconditioning
in rabbits and rats.103,104 Since then, it has been well established that,
in addition to hyperlipidaemia, most of the major co-morbidities of
IHD as well as their co-medications may lead to the loss or attenuation
of cardioprotection by ischaemic or pharmacological conditioning
[see, for extensive review, ref. (96,97)]. However, most experimental
studies on cardioprotection are still undertaken in healthy juvenile
animal models, although IHD in humans is a complex disorder caused
by or associated with cardiovascular risk factors and co-morbidities,
including hypertension, hyperlipidaemia, diabetes, and aging. These
risk factors induce fundamental alterations in cellular signalling cascades
that affect the severityof I/R injuryand the responses tocardioprotective
interventions. In thehypertensiveheartwith orwithoutLVhypertrophy,
while cardioprotection by preconditioning is still present, reduction in
MI size by ischaemic postconditioning appears to be lost.97,105,106
Most of the preclinical studies, together with some small scale clinical
studies, have shown that hyperlipidaemia per se, but not the develop-
ment of atherosclerosis, leads to a significant aggravation of myocardial
I/R injury and to attenuation of the cardioprotective effect of both early
and late preconditioning and postconditioning [reviewed in ref. (96,97)].
The majority of both preclinical and clinical data suggest that the chron-
ically diabetic heart is more susceptible to I/R injury, and that the cardi-
oprotective effect of ischaemic and pharmacological preconditioning
and postconditioning is impaired [reviewed in ref. (97,107)]. Table 2 pro-
vides a summary of the effect of co-morbidities on the response to I/R
injury and cardioprotection.
In summary, because co-morbidities can affect the cardioprotective efficacy
of novel therapies, testing in co-morbid animal MI models should be part of the
preclinical assessment of novel cardioprotective therapies.
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4.3.5 Concomitant medication
Many cardioprotective drugs—when administered alone prior to
ischaemia and/or reperfusion—reduce irreversible myocardial injury;
i.e. attenuate infarct size and potentially reduce patient morbidity and
mortality (Table 3). However, in clinical reality, more than one drug is
needed to adequately treat patients and therefore, drug–drug interac-
tions must be taken into account. For example, the beneficial effects
of angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin
receptor (AT)1-receptorantagonists areattenuatedwhencyclooxygen-
ase (COX) inhibitors are simultaneously applied,108 and the beneficial
effects of metformin in diabetic patients is lost when co-administered
with the potassium adenosine triphosphate channel blocker glyburide,
as is the protection by remote ischaemic preconditioning in diabetic
patients receiving sulfonylureas.109 Aspirin at low dose does not affect
MI size, whereas at high dose—blocking COX—interferes with cardio-
protective interventions.110 Platelet inhibition by clopidogrel, prasugrel,
or ticagrelor has been shown to reduce infarct size in animal models and
some data exist to also prove clinical efficacy.111 The mechanisms
involved have been suggested to involve nitric oxide (clopidogrel) or ad-
enosine (ticagrelor). Potentially, many more interactions will occur in
patients with multiple medications. In healthy hearts, most drugs
when applied acutely or chronically will interfere with endogenous car-
dioprotection, except for ACE inhibitors and AT1-receptor antagonists,
which lower the threshold to achieve endogenous cardioprotection.
However, in hearts from animals or patients suffering co-morbidities,
some drugs might restore the otherwise lost possibility to induce
endogenous cardioprotection [for extensive review on cardioprotec-
tion and co-medication, see review in ref. (96,97)].
4.4 Other confounding factors
In addition to the effect modifiers outlined in previous sections, several
other factors have now been identified that likely influence the success
of cardioprotective strategies and should therefore be considered po-
tential confounders in the translational process.
4.4.1 Circadian rhythms
The majority of preclinical experiments do not take into account the
effect of the time of day on the efficacy of the novel cardioprotective
therapy. Both cardiovascular physiology and pathophysiology are pro-
foundly influenced by circadian rhythms, biorhythms that persist with
a period of 24 h, consistent with our regular day/night rhythm.112
A central ‘master’ clock is located in the brain and orchestrates
time-of-day-dependent function of nearby and distant tissues via
neurohumoral signals. Each adult mammalian cell also has its own
‘peripheral’ clock that can regulate circadian variations in cell function
autonomously.113 In the heart this translates into, among others, a circa-
dian variation in tolerance to I/R injury resulting in circadian variation in
MI size and cardiac function at least in mice undergoing experimental
AMI.114 MI size and LV function after reperfused STEMI in humans
are also correlated with the time-of-day onset of symptoms even
when corrected for confounders,115,116 although this notion is not
unequivocal.117 Importantly, the amplitude of circadian variation but
also the capacity of animals to adapt to externally induced changes in
day–night rhythms are reduced with age.118 Thus, when considering
the use of aged animals, one has to realize that the circadian pattern of
young animals cannot simply be extrapolated to their older counter-
parts. Co-morbidities such as diabetes can further disturb circadian
rhythms as has been demonstrated in patients.112,119
Notably, for practical reasons, most animal facilities follow a ‘lights on
at daytime, lights off at night-time’ setting. Thus, preclinical experiments
are typically performed athuman daytime, which represents the subject-
ive night for nocturnal animals such as rodents and may add an additional
difference between preclinical and clinical success of a tested cardiopro-
tective strategy. In addition, seasonal variation is present in humans120
but not in animals housed under standard conditions, although seasonal
variation can be mimicked through light settings.121 Experimental design
for preclinical cardioprotection studies should therefore at least report
and ideally match for the circadian phase in which the injury and thera-
peutic intervention were initiated.
4.4.2 Depression and stress
Depression and psychological stress are commonly present in patients
with IHD and are independently associated with increased cardiovascu-
lar morbidity and mortality.122 In experimental models, depression alters
cardioprotective strategies,123 and researchers usually avoid exposing
theiranimals tostressprior toexperiments as it often affects thebeneficial
outcome of pharmacological and mechanical cardioprotective strategies.
Although this strategy leads to a higher sensitivity for the result of the
tested intervention, it reduces its translational applicability in a manner
similar to the somatic co-morbidities. Especially when testing strategies
that interfere directly or indirectly with stress-inducible pathways, such
as the adrenaline–cortisol axis, one should consider that the natural
response in patients may mimic or counteract, respectively, the experi-
mental intervention.
4.4.3 Environmental factors
Smoking, air pollution, oxidative stress, temperature, noise, and likely
other yet unknown factors can induce or inhibit signalling pathways
in the cardiomyocyte and other relevant cell types. Besides causing
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Table 2 Effect of different co-morbidities on the susceptibility to myocardial I/R injury and the response to cardioprotection
elicited by ischaemic preconditioning, ischaemic postconditioning, and remote ischaemic conditioning in experimental animal
MI models. Modified from Ref 96
Co-morbidity I/R injury Ischaemic preconditioning Ischaemic postconditioning Remote ischaemic conditioning
Aging Increased Attenuated response Attenuated response Not tested
Hypertension No difference No difference Attenuated response Not tested
Hyperlipidaemia Increased Attenuated response Attenuated response Not tested
Diabetes Increased Attenuated response Attenuated response Attenuated response
Kidney failure Increased No difference No difference No difference
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failure to translate preclinical to clinical results, this issue may already
present at an earlier stage as a reproducibility problem between
laboratories. For example, Kaljusto et al.124 aimed to identify a robust
postconditioning protocol in rat and mouse heart and found that post-
conditioning in rat hearts in vivo was protective in one laboratory, but
not the other laboratory applying the same protocol. Some efforts
have been made to characterize or even therapeutically translate the
mechanisms by which these environmental aspects may influence the
damage induced by I/R injury and the therapeutic effects of cardiopro-
tection.125,126 The development of systems biology approaches may
possibly in the future provide additional means of taking into account
these environmental and psychological factors that are currently very
hard to correct for. The problem with potential confounding effects in
the laboratory environment may be overcome by multicentre testing
of the novel cardioprotective therapy.
In summary, careful attention must be given to the animal species
selected to assess the novel cardioprotective therapy. A variety of factors
(including age, gender, co-morbidities, concomitant medication, circadian
rhythms, and environmental stress) may confound the intrinsic response to
acute I/R injury and confound the cardioprotective efficacy of the novel
therapy under investigation. These factors should therefore be taken into
account when preclinically assessing the clinical potential of the novel cardi-
oprotective therapy.
4.5 Looking towards the future
Having endured for many years the laments of being ‘lost in transla-
tion’,40 the field of cardioprotection appears, at long last, to be back
on the map. There have been positive results reducing infarct size
using both the beta-blocker metoprolol and the insulin secretagogue
exenatide.10,74,127
The results of early preclinical studies investigating the ability
of beta-blockers to protect the heart had been mixed.128 However,
a more recent study in pigs was able to take advantage of delayed-
enhancement cardiac MRI in order to accurately quantify the extent
of myocardial necrosis in vivo, and used a clinically relevant study
design with metoprolol administered after the onset of ischaemia
but before the onset of reperfusion.129,130 The positive results of this
study enabled the investigators to progress to the METOCARD-CNIC
clinical study, which proved successful in reducing infarct size and
increasing LV ejection fraction in patients with anterior Killip class II
or less STEMI undergoing PPCI.10
Similarly, exenatide was first shown to be cardioprotective during
reperfusion in isolated rat hearts.131 Importantly, this was subsequently
confirmed in a pig model by an independent group,132 before progres-
sing to an appropriately designed study,133 which demonstrated
improved myocardial salvage in patients undergoing PPCI who received
exenatide.74
Other cardioprotective drugs such as cyclosporine A,11 as well as
other modalities such as remote ischaemic preconditioning,13,134,135
have undergone extensive preclinical testing and have now made the
translation to small proof-of-concept studies and larger studies. With
optimism re-instilled, the outcome of these studies is awaited with
much interest.
However, it must be borne in mind that these positive data are from
small proof-of-concept clinical studies, and large adequately powered
multicentre studies are required to confirm their cardioprotective
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Table 3 Effect of different concomitant medication on the susceptibility to myocardial I/R injury and the response to
cardioprotection elicited by ischaemic preconditioning, ischaemic postconditioning, and remote ischaemic conditioning in
experimental animal MI models. Modified from Ref 96
Drug class I/R injury Ischaemic preconditioning
(co-morbidity)
Ischaemic postconditioning
(co-morbidity)
Remote ischaemic
conditioning
Acute nitrate
Nitrate tolerant
Decreased
Increased
No tested
Attenuated response
Not tested
Attenuated response
Not tested
No difference
Acute statin
Chronic statin
Decreased/no
difference
Decreased/no
difference
Attenuated response/enhanced response
(hyperlipid)
No difference
No difference
Attenuated response
Not tested
Not tested
Beta-blocker Decreased
(drug-dependent)
Attenuated response/no difference/
enhanced response (stenosis)
Attenuated response/no difference/
enhanced response (stenosis)
Attenuated response
ACE inhibitor Decreased Enhanced response (DM) Attenuated response Not tested
AT1 antagonist Decreased Enhanced response (LVH) Not tested Not tested
Diabetic drugs
Metformin Decreased Not tested Not tested Not tested
KATP blocker No difference Attenuated response (drug-dependent) Attenuated response (drug-dependent) Attenuated
DPP-4
inhibitor
Decreased Not tested Not tested Not tested
GLP-1
analogue
Decreased Not tested Not tested Not tested
Insulin Decreased Not tested Not tested Not tested
COX inhibitor Decreased/no
difference
Attenuated response Attenuated response Not tested
In some studies, the effect of the concomitant medication was tested using an animal MI model with co-morbidities such as diabetes (DM), hyperlipidaemia (hyperlipid), left ventricular
hypertrophy (LVH), or chronic ischaemia (stenosis). DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1.
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effect, and to determine whether they can actually improve long-term
relevant clinical outcomes such as cardiac death and hospitalization
for heart failure.
5. Recommendations
In this ESC WG Position Paper, we have discussed several areas in which
the current approach to the preclinical assessment of novel cardiopro-
tective therapies can be improved. In Figure 1, we provide an illustrated
overview of the different experimental approaches that exist in the
preclinical assessment of novel cardioprotective therapies with an
increase in complexity of the I/R injury model as one moves from cell-
based studies, ex vivo isolated heart studies, to in vivo large animal recov-
ery AMI models. Adding to this complexity is the need to take into
account the effect of confounding factors such as co-morbidities (such
as age, diabetes, hypertension, dyslipidaemia, etc.) and concomitant
medication (such as morphine, nitrates, sulfonylureas, nicorandil, etc.)
in the preclinical assessment.
To this translational pathway, we would like to propose the setting up
of an European network of research centres of different animal AMI
models to test one particular novel cardioprotective therapy using a
multicentre randomized controlled study approach, in a similar
manner to the proposed CAESAR network in the USA (http://www.
nihcaesar.org).
In summary, we would like to make the following recommendations
when assessing the clinical potential of a novel cardioprotective
therapy discovered in the research laboratory:
† The novel cardioprotective therapy has been demonstrated to offer
unequivocable efficacy (in terms of MI size reduction) in all experi-
mental I/R injury models tested, including a large animal I/R injury
model.
† The novel cardioprotective therapy has been demonstrated to be
effective in the presence of oneof more co-morbidities (age, diabetes,
and dyslipidaemia) and/or concomitant medication (known to poten-
tially have an impact on cardioprotection).
† The novel cardioprotective therapy should be investigated in preclin-
ical studies within a research network of centres using a multicentre,
randomized controlled, double-blinded, and study approach.
6. Conclusions
The translation of novel cardioprotective therapies from the research
laboratory into the clinical setting to improve clinical outcomes in IHD
patients has been challenging. Despite the discovery of hundreds of
novel cardioprotective therapies in the preclinical laboratory setting,
none of these have been incorporated into routine clinical practice for
patient benefit. This has been due, in part, to the failure to rigorously
assess the novel cardioprotective therapy in the preclinical setting
Figure 1 The experimental I/R injury model used for testing the cardioprotective strategy in the preclinical setting needs to increase in complexity the
closer one gets to the clinical setting. On top of this is the need to take into account confounders of cardioprotection such as co-morbidities and
co-medication. Hopefully, rigorous testing of the cardioprotective strategy using this scheme as a guide should increase the likelihood of translating the
therapy into the clinical setting (more detail is given in the text).
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before embarking on patient studies. In this ESC WG Position Paper, we
provide recommendations for optimizing this process in order to
improve the translation of novel cardioprotective therapies discovered
in the research laboratory into improved clinical outcomes for IHD
patients.
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